Resistance

In contrast to other NNRTIs, more than one resistance mutation needs to develop, in order to bring about resistance to etravirine.1 2 The presence of the most common NNRTI mutation, K103N, did not affect the treatment response in individuals on etravirine in the DUET studies; however, the presence at baseline of V179D, V179F, V179T, Y181V, or G190S was associated with a decreased virologic response to etravirine.3 4

Tibotec, manufacturer of etravirine, has noted that cross-resistance to efavirenz and/or nevirapine is to be expected after virologic failure while on an etravirine-containing regimen.

References

  1. Brillant JE et al. In vitro resistance development for a second-generation NNRTI: TMC125. 13th International HIV Drug Resistance Workshop, Costa Adeje, abstract 16, 2004
  2. Vingerhoets J et al. TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol 79: 12773-12782, 2005
  3. Madruga JV et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet 370: 29-38, 2007
  4. Lazzarin A et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet 370: 39-48, 2007
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.